FDA Accepts Supplement for Repatha (Evolocumab) by Amgen
The FDA has accepted a supplemental application for Repatha (evolocumab) from Amgen.
Asset / Drug
Drug and asset intelligence for Repatha with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
PCSK9 Inhibitor
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.